View printer-friendly version
« Back
January 26, 2005 9:52 a.m.
Teva Announces Global In-Market Fourth Quarter Sales Of Copaxone® Increased 26% To $261 Million

Annual Sales Increased 30% To Record $936 Million

Jerusalem, Israel, January 26, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of Copaxone® reached $261 million in the fourth quarter ended December 31, 2004, an increase of 26% over the comparable quarter of 2003. For the full year 2004, global in-market sales of Copaxone® reached an all-time high of $936 million, an increase of 30% over 2003.

U.S. sales in the fourth quarter 2004 increased 23% over the fourth quarter 2003 to $175 million. For the full year 2004, U.S. sales increased 26% to $625 million compared to last year.

According to IMS data, Copaxone® was the market leader in the U.S. in terms of new prescriptions for the second half of 2004 and reached an all-time high market share (total prescriptions) of 32.6% in December.

For the fourth quarter 2004, sales outside the U.S., mainly in Europe, increased by 31% over the comparable quarter of 2003, to $86 million. For the entire year, sales outside the U.S. increased by 38% to $311 million.

"Copaxone's superior history of continued efficacy and safety is demonstrated by the exceptional growth in both sales and market share. As more and more doctors prescribe Copaxone to effectively address all aspects of their patients' disease, we are increasing our global market share. We are especially pleased with our growth in the U.S., where we are quickly becoming the leading MS treatment," said Israel Makov, President and CEO of Teva.

Following the recent Sanofi-Aventis merger, the merged group has modified the Aventis products sales reporting, which accounts for the difference in the sales figures reported by Teva and Sanofi-Aventis. The sales figures in this Teva press release are consistent with previous reported results and include additional $13 million in direct non-U.S. sales by Teva.

Teva plans to release its full year 2004 financial results on Tuesday, February 15, 2005.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone® sales, including potential competition from the expected launch of Tysabri®/Antegren®, Teva's ability to rapidly integrate the operations of acquired businesses, including its acquisition of Sicor Inc., regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.